{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:54:03Z","timestamp":1793332443275,"version":"4.5.0"},"reference-count":93,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T00:00:00Z","timestamp":1675123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"European Union\u2019s Horizon 2020"},{"DOI":"10.13039\/501100000272","name":"NIHR","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Marie Sk\u0142odowska-Curie","award":["801076"],"award-info":[{"award-number":["801076"]}]},{"name":"GlobalP3HS"},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"crossref","award":["SNSF IZSTZ0_190277"],"award-info":[{"award-number":["SNSF IZSTZ0_190277"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,14]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aims<\/jats:title><jats:p>Optimal endovascular management of intermittent claudication (IC) remains disputed. This systematic review and meta-analysis compares efficacy and safety outcomes for balloon angioplasty (BA), bare-metal stents (BMS), drug-coated balloons (DCB), drug-eluting stents (DES), covered stents, and atherectomy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and results<\/jats:title><jats:p>Electronic databases were searched for randomized, controlled trials (RCT) from inception through November 2021. Efficacy outcomes were primary patency, target-lesion revascularization (TLR), and quality-of-life (QoL). Safety endpoints were all-cause mortality and major amputation. Outcomes were evaluated at short-term (&amp;lt;1 year), mid-term (1\u20132 years), and long-term (\u22652 years) follow-up. The study was registered on PROSPERO (CRD42021292639). Fifty-one RCTs enrolling 8430 patients\/lesions were included. In femoropopliteal disease of low-to-intermediate complexity, DCBs were associated with higher likelihood of primary patency [short-term: odds ratio (OR) 3.21, 95% confidence interval (CI) 2.44\u20134.24; long-term: OR 2.47, 95% CI 1.93\u20133.16], lower TLR (short-term: OR 0.33, 95% CI 0.22\u20130.49; long-term: OR 0.42, 95% CI 0.29\u20130.60) and similar all-cause mortality risk, compared with BA. Primary stenting using BMS was associated with improved short-to-mid-term patency and TLR, but similar long-term efficacy compared with provisional stenting. Mid-term patency (OR 1.64, 95% CI 0.89\u20133.03) and TLR (OR 0.50, 95% CI 0.22\u20131.11) estimates were comparable for DES vs. BMS. Atherectomy, used independently or adjunctively, was not associated with efficacy benefits compared with drug-coated and uncoated angioplasty, or stenting approaches. Paucity and heterogeneity of data precluded pooled analysis for aortoiliac disease and QoL endpoints.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Certain devices may provide benefits in femoropopliteal disease, but comparative data in aortoiliac arteries is lacking. Gaps in evidence quantity and quality impede identification of the optimal endovascular approach to IC.<\/jats:p><\/jats:sec>","DOI":"10.1093\/eurheartj\/ehac722","type":"journal-article","created":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T19:08:26Z","timestamp":1675278506000},"page":"935-950","source":"Crossref","is-referenced-by-count":73,"title":["Endovascular revascularization strategies for aortoiliac and femoropopliteal artery disease: a meta-analysis"],"prefix":"10.1093","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8475-2861","authenticated-orcid":false,"given":"David","family":"Koeckerling","sequence":"first","affiliation":[{"name":"Division of Angiology, Swiss Cardiovascular Center, Inselspital, Bern University Hospital, University of Bern , Freiburgstrasse 18, 3010 Bern , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Francis","family":"Raguindin","sequence":"additional","affiliation":[{"name":"Institute of Social and Preventive Medicine (ISPM), University of Bern , Mittelstrasse 43, 3012 Bern , Switzerland"},{"name":"Swiss Paraplegic Research , Guido A. Z\u00e4ch Str. 1, 6207 Nottwil , Switzerland"},{"name":"Faculty of Health Sciences and Medicine, University of Lucerne , Frohburgstrasse, 36002 Lucerne , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lum","family":"Kastrati","sequence":"additional","affiliation":[{"name":"Institute of Social and Preventive Medicine (ISPM), University of Bern , Mittelstrasse 43, 3012 Bern , Switzerland"},{"name":"Graduate School for Health Sciences, University of Bern , Mittelstrasse 43, 3012 Bern , Switzerland"},{"name":"Department of Diabetes, Endocrinology, Nutritional Medicine and Metabolism, Inselspital, Bern University Hospital, University of Bern , Freiburgstrasse 18, 3010 Bern , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Bernhard","sequence":"additional","affiliation":[{"name":"Division of Angiology, Swiss Cardiovascular Center, Inselspital, Bern University Hospital, University of Bern , Freiburgstrasse 18, 3010 Bern , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5483-9608","authenticated-orcid":false,"given":"Joseph","family":"Barker","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Sciences, University of Leicester , University Rd, Leicestershire LE1 7RH , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Carolina","family":"Quiroga Centeno","sequence":"additional","affiliation":[{"name":"Department of Surgery, Universidad Industrial de Santander , Cl. 9 Cra 27, Bucaramanga, Santander , Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5538-6073","authenticated-orcid":false,"given":"Hamidreza","family":"Raeisi-Dehkordi","sequence":"additional","affiliation":[{"name":"Institute of Social and Preventive Medicine (ISPM), University of Bern , Mittelstrasse 43, 3012 Bern , Switzerland"},{"name":"Graduate School for Health Sciences, University of Bern , Mittelstrasse 43, 3012 Bern , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farnaz","family":"Khatami","sequence":"additional","affiliation":[{"name":"Institute of Social and Preventive Medicine (ISPM), University of Bern , Mittelstrasse 43, 3012 Bern , Switzerland"},{"name":"Community Medicine Department, Tehran University of Medical Sciences , PourSina St., Tehran 1417613151 , Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christa","family":"Niehot","sequence":"additional","affiliation":[{"name":"Literature Searches Support , 3314SC Dordrecht , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Lejay","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery and Kidney Transplantation, University of Strasbourg , 4 rue Kirschleger, 67085 Strasbourg , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoltan","family":"Szeberin","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery, Semmelweis University , XII. V\u00e1rosmajor u. 68., 1122 Budapest , Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian-Alexander","family":"Behrendt","sequence":"additional","affiliation":[{"name":"Department of Vascular and Endovascular Surgery, Asklepios Clinic Wandsbek, Asklepios Medical School , Alphonsstra\u00dfe 14, 22043 Hamburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2670-2268","authenticated-orcid":false,"given":"Joakim","family":"Nordanstig","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery and Institute of Medicine, Department of Molecular and Clinical Medicine, Sahlgrenska University Hospital and Academy, Gothenburg University , Bl\u00e5 str\u00e5ket 5, 413 45 Gothenburg , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3235-3073","authenticated-orcid":false,"given":"Taulant","family":"Muka","sequence":"additional","affiliation":[{"name":"Institute of Social and Preventive Medicine (ISPM), University of Bern , Mittelstrasse 43, 3012 Bern , Switzerland"},{"name":"Epistudia , 3011 Bern , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Baumgartner","sequence":"additional","affiliation":[{"name":"Division of Angiology, Swiss Cardiovascular Center, Inselspital, Bern University Hospital, University of Bern , Freiburgstrasse 18, 3010 Bern , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,1,31]]},"reference":[{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1161\/CIRCRESAHA.116.303849","article-title":"Epidemiology of peripheral artery disease","volume":"116","author":"Criqui","year":"2015","journal-title":"Circ Res"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.ejvs.2019.12.034","article-title":"Editor\u2019\u2019s choice - long term survival after femoropopliteal artery revascularisation with paclitaxel coated devices: a propensity score matched cohort analysis","volume":"59","author":"Behrendt","year":"2020","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.amjcard.2020.05.015","article-title":"Meta-Analysis comparing endovascular treatment modalities for femoropopliteal peripheral artery disease","volume":"128","author":"Khan","year":"2020","journal-title":"Am J Cardiol"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jvs.2016.08.095","article-title":"A network meta-analysis of randomized controlled trials comparing treatment modalities for de novo superficial femoral artery occlusive lesions","volume":"65","author":"Antonopoulos","year":"2017","journal-title":"J Vasc Surg"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.jvs.2019.01.080","article-title":"Systematic review and updated meta-analysis of the use of drug-coated balloon angioplasty versus plain old balloon angioplasty for femoropopliteal arterial disease","volume":"70","author":"Caradu","year":"2019","journal-title":"J Vasc Surg"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s10654-019-00576-5","article-title":"A 24-step guide on how to design, conduct, and successfully publish a systematic review and meta-analysis in medical research","volume":"35","author":"Muka","year":"2020","journal-title":"Eur J Epidemiol"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","DOI":"10.1002\/9781119536604","author":"Higgins","year":"2019","journal-title":"Cochrane Handbook for Systematic Reviews of Interventions"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 Statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3163\/1536-5050.104.3.014","article-title":"De-duplication of database search results for systematic reviews in EndNote","volume":"104","author":"Bramer","year":"2016","journal-title":"J Med Libr Assoc"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"2s","DOI":"10.1016\/j.jvs.2014.12.009","article-title":"Society for vascular surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication","volume":"61","author":"Conte","year":"2015","journal-title":"J Vasc Surg"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","article-title":"2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European society for vascular surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European stroke organization (ESO)The task force for the diagnosis and treatment of peripheral arterial diseases of the European society of cardiology (ESC) and of the European society for vascular surgery (ESVS)","volume":"39","author":"Aboyans","year":"2017","journal-title":"Eur Heart J"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1161\/CIRCINTERVENTIONS.111.962324","article-title":"Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month zilver PTX randomized study results","volume":"4","author":"Dake","year":"2011","journal-title":"Circ Cardiovasc Interv"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1016\/j.jacc.2013.03.034","article-title":"Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the zilver PTX randomized and single-arm clinical studies","volume":"61","author":"Dake","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1161\/CIRCULATIONAHA.115.016900","article-title":"Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the zilver PTX randomized trial","volume":"133","author":"Dake","year":"2016","journal-title":"Circulation"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"Rob 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13643-015-0083-6","article-title":"Handling trial participants with missing outcome data when conducting a meta-analysis: a systematic survey of proposed approaches","volume":"4","author":"Akl","year":"2015","journal-title":"Syst Rev"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"e57132","DOI":"10.1371\/journal.pone.0057132","article-title":"Addressing dichotomous data for participants excluded from trial analysis: a guide for systematic reviewers","volume":"8","author":"Akl","year":"2013","journal-title":"PLoS ONE"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/S0140-6736(97)09508-1","article-title":"Randomised comparison of primary stent placement versus primary angioplasty followed by selective stent placement in patients with iliac-artery occlusive disease. Dutch iliac stent trial study group","volume":"351","author":"Tetteroo","year":"1998","journal-title":"Lancet"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1161\/01.CIR.99.24.3155","article-title":"Health-related quality of life after angioplasty and stent placement in patients with iliac artery occlusive disease: results of a randomized controlled clinical trial. The Dutch iliac stent trial study group","volume":"99","author":"Bosch","year":"1999","journal-title":"Circulation"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1148\/radiol.2322030725","article-title":"Long-term cardiovascular morbidity, mortality, and reintervention after endovascular treatment in patients with iliac artery disease: the Dutch iliac stent trial study","volume":"232","author":"Klein","year":"2004","journal-title":"Radiology"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1148\/radiol.2382041053","article-title":"Dutch Iliac stent trial: long-term results in patients randomized for primary or selective stent placement","volume":"238","author":"Klein","year":"2006","journal-title":"Radiology"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1002\/bjs.9197","article-title":"Randomized clinical trial of stents versus angioplasty for the treatment of iliac artery occlusions (STAG trial)","volume":"100","author":"Goode","year":"2013","journal-title":"Br J Surg"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1016\/j.jcin.2017.05.015","article-title":"Self-Expanding versus balloon-expandable stents for iliac artery occlusive disease: the randomized ICE trial","volume":"10","author":"Krankenberg","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.jvs.2011.06.097","article-title":"A comparison of covered vs bare expandable stents for the treatment of aortoiliac occlusive disease","volume":"54","author":"Mwipatayi","year":"2011","journal-title":"J Vasc Surg"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jvs.2016.02.064","article-title":"Durability of the balloon-expandable covered versus bare-metal stents in the covered versus balloon expandable stent trial (COBEST) for the treatment of aortoiliac occlusive disease","volume":"64","author":"Mwipatayi","year":"2016","journal-title":"J Vasc Surg"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1161\/CIRCULATIONAHA.117.028893","article-title":"Stellarex drug-coated balloon for treatment of femoropopliteal disease: twelve-month outcomes from the randomized ILLUMENATE pivotal and pharmacokinetic studies","volume":"136","author":"Krishnan","year":"2017","journal-title":"Circulation"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMoa0706356","article-title":"Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg","volume":"358","author":"Tepe","year":"2008","journal-title":"N Engl J Med"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jcin.2014.07.023","article-title":"Angioplasty of femoral-popliteal arteries with drug-coated balloons: 5-year follow-up of the THUNDER trial","volume":"8","author":"Tepe","year":"2015","journal-title":"JACC Cardiovasc Interv"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1177\/1526602817725062","article-title":"Short-term results of the RAPID randomized trial of the legflow paclitaxel-eluting balloon with supera stenting vs supera stenting alone for the treatment of intermediate and long superficial femoral artery lesions","volume":"24","author":"de Boer","year":"2017","journal-title":"J Endovasc Ther"},{"key":"2023031404455702300_","first-page":"679","article-title":"Drug coated balloon supported supera stent versus supera stent in intermediate and long-segment lesions of the superficial femoral artery: 2-year results of the RAPID trial","volume":"60","author":"de Boer","year":"2019","journal-title":"J Cardiovasc Surg (Torino"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1161\/CIRCULATIONAHA.114.011004","article-title":"Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial","volume":"131","author":"Tepe","year":"2015","journal-title":"Circulation"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1016\/j.jacc.2015.09.063","article-title":"Durability of treatment effect using a drug-coated balloon for femoropopliteal lesions: 24-month results of IN.PACT SFA","volume":"66","author":"Laird","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"e005891","DOI":"10.1161\/CIRCINTERVENTIONS.117.005891","article-title":"Treatment effect of drug-coated balloons is durable to 3 years in the femoropopliteal arteries: long-term results of the IN.PACT SFA randomized trial","volume":"11","author":"Schneider","year":"2018","journal-title":"Circ Cardiovasc Interv"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"e007702","DOI":"10.1161\/CIRCINTERVENTIONS.118.007702","article-title":"Long-Term clinical effectiveness of a drug-coated balloon for the treatment of femoropopliteal lesions","volume":"12","author":"Laird","year":"2019","journal-title":"Circ Cardiovasc Interv"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1016\/j.jcin.2018.07.041","article-title":"Drug-Coated balloon angioplasty compared with uncoated balloons in the treatment of 200 Chinese patients with severe femoropopliteal lesions: 24-month results of AcoArt I","volume":"11","author":"Xu","year":"2018","journal-title":"JACC Cardiovasc Interv"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.jvs.2021.01.041","article-title":"Long-term safety and efficacy of angioplasty of femoropopliteal artery disease with drug-coated balloons from the AcoArt I trial","volume":"74","author":"Xu","year":"2021","journal-title":"J Vasc Surg"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1161\/CIRCULATIONAHA.116.026493","article-title":"Low-Dose paclitaxel-coated versus uncoated percutaneous transluminal balloon angioplasty for femoropopliteal peripheral artery disease: one-year results of the ILLUMENATE European randomized clinical trial (randomized trial of a novel paclitaxel-coated percutaneous angioplasty balloon)","volume":"135","author":"Schroeder","year":"2017","journal-title":"Circulation"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1016\/j.jcin.2018.08.034","article-title":"Sustainable antirestenosis effect with a low-dose drug-coated balloon: the ILLUMENATE European randomized clinical trial 2-year results","volume":"11","author":"Brodmann","year":"2018","journal-title":"JACC Cardiovasc Interv"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/1526602817745565","article-title":"Drug-Coated balloon vs standard percutaneous transluminal angioplasty for the treatment of atherosclerotic lesions in the superficial femoral and proximal popliteal arteries: one-year results of the MDT-2113 SFA Japan randomized Trial","volume":"25","author":"Iida","year":"2018","journal-title":"J Endovasc Ther"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ccd.28048","article-title":"Drug-coated balloon versus uncoated percutaneous transluminal angioplasty for the treatment of atherosclerotic lesions in the superficial femoral and proximal popliteal artery: 2-year results of the MDT-2113 SFA Japan randomized trial","volume":"93","author":"Iida","year":"2019","journal-title":"Catheter Cardiovasc Interv"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1177\/1526602820948240","article-title":"Three-Year results of the IN.PACT SFA Japan trial comparing drug-coated balloons with percutaneous transluminal angioplasty","volume":"27","author":"Soga","year":"2020","journal-title":"J Endovasc Ther"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s00270-017-1713-2","article-title":"Angiographic and clinical outcomes after treatment of femoro-popliteal lesions with a novel paclitaxel-matrix-coated balloon catheter","volume":"40","author":"Tepe","year":"2017","journal-title":"Cardiovasc Intervent Radiol"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1007\/s00270-018-1940-1","article-title":"Two-Year clinical outcomes of the CONSEQUENT trial: can femoropopliteal lesions be treated with sustainable clinical results that are economically sound?","volume":"41","author":"Albrecht","year":"2018","journal-title":"Cardiovasc Intervent Radiol"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1177\/1526602817710770","article-title":"Six-Month results from the initial randomized study of the ranger paclitaxel-coated balloon in the femoropopliteal segment","volume":"24","author":"Bausback","year":"2017","journal-title":"J Endovasc Ther"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jcin.2018.01.276","article-title":"12-Month Results from the first-in-human randomized study of the ranger paclitaxel-coated balloon for femoropopliteal treatment","volume":"11","author":"Steiner","year":"2018","journal-title":"JACC Cardiovasc Interv"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1016\/j.jcin.2018.07.029","article-title":"Clinical randomized trial evaluating novel, microcrystalline, and biocompatible polymer paclitaxel-coated balloon for the treatment of femoropopliteal occlusive disease: the BIOPAC Trial","volume":"11","author":"Buszman","year":"2018","journal-title":"JACC Cardiovasc Interv"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/1358863X20988360","article-title":"Microcrystalline paclitaxel-coated balloon for revascularization of femoropopliteal artery disease: three-year outcomes of the randomized BIOPAC trial","volume":"26","author":"Nowakowski","year":"2021","journal-title":"Vasc Med"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"e1633","DOI":"10.4244\/EIJ-D-19-00292","article-title":"Efficacy and safety of a novel paclitaxel-nano-coated balloon for femoropopliteal angioplasty: one-year results of the EffPac trial","volume":"15","author":"Teichgr\u00e4ber","year":"2020","journal-title":"EuroIntervention"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1148\/radiol.2020191619","article-title":"Drug-coated balloon angioplasty of femoropopliteal lesions maintained superior efficacy over conventional balloon: 2-year results of the randomized EffPac Trial","volume":"295","author":"Teichgr\u00e4ber","year":"2020","journal-title":"Radiology"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1161\/CIRCULATIONAHA.116.025329","article-title":"Randomized comparison of paclitaxel-eluting balloon and stenting versus plain balloon plus stenting versus directional atherectomy for femoral artery disease (ISAR-STATH)","volume":"135","author":"Ott","year":"2017","journal-title":"Circulation"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa1406235","article-title":"Trial of a paclitaxel-coated balloon for femoropopliteal artery disease","volume":"373","author":"Rosenfield","year":"2015","journal-title":"N Engl J Med"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jcin.2021.03.021","article-title":"1-Year Results from the RANGER II SFA randomized trial of the ranger drug-coated balloon","volume":"14","author":"Sachar","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jcin.2013.05.022","article-title":"The LEVANT I (lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty","volume":"7","author":"Scheinert","year":"2014","journal-title":"JACC Cardiovasc Interv"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/1526602814564383","article-title":"Paclitaxel-releasing balloon in femoropopliteal lesions using a BTHC excipient: twelve-month results from the BIOLUX P-I randomized trial","volume":"22","author":"Scheinert","year":"2015","journal-title":"J Endovasc Ther"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1007\/s00270-019-02309-3","article-title":"The randomized freeway stent study: drug-eluting balloons outperform standard balloon angioplasty for postdilatation of nitinol stents in the SFA and PI segment","volume":"42","author":"Tacke","year":"2019","journal-title":"Cardiovasc Intervent Radiol"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1161\/CIRCULATIONAHA.107.735985","article-title":"Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial","volume":"118","author":"Werk","year":"2008","journal-title":"Circulation"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1161\/CIRCINTERVENTIONS.112.971630","article-title":"Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial","volume":"5","author":"Werk","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ijcard.2020.10.060","article-title":"Reewarm\u2122 PTX drug-coated balloon in the treatment of femoropopliteal artery disease: a multi-center, randomized controlled trial in China","volume":"326","author":"Ye","year":"2021","journal-title":"Int J Cardiol"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"686267","DOI":"10.3389\/fcvm.2021.686267","article-title":"Twelve-Month results from the first-in-China prospective, multi-center, randomized, controlled study of the FREEWAY paclitaxel-coated balloon for femoropopliteal treatment","volume":"8","author":"Zhang","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1067\/mva.2003.155","article-title":"Systematic versus selective stent placement after superficial femoral artery balloon angioplasty: a multicenter prospective randomized study","volume":"37","author":"Becquemin","year":"2003","journal-title":"J Vasc Surg"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1051-0443(07)61397-9","article-title":"PTA Versus Palmaz stent placement in femoropopliteal artery obstructions: a multicenter prospective randomized study","volume":"12","author":"Cejna","year":"2001","journal-title":"J Vasc Interv Radiol"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00270-012-0492-z","article-title":"Randomized trial of the SMART stent versus balloon angioplasty in long superficial femoral artery lesions: the SUPER study","volume":"36","author":"Chalmers","year":"2013","journal-title":"Cardiovasc Intervent Radiol"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/ccd.22128","article-title":"Balloon angioplasty versus stenting with nitinol stents in intermediate length superficial femoral artery lesions","volume":"74","author":"Dick","year":"2009","journal-title":"Catheter Cardiovasc Interv"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1055\/s-2004-813377","article-title":"PTA Versus palmaz stent placement in femoropopliteal artery stenoses: results of a multicenter prospective randomized study (REFSA)","volume":"176","author":"Grenacher","year":"2004","journal-title":"Rofo"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1177\/1526602819826591","article-title":"Self-Expanding nitinol stent vs percutaneous transluminal angioplasty in the treatment of femoropopliteal lesions: 3-year data from the SM-01 Trial","volume":"26","author":"Iida","year":"2019","journal-title":"J Endovasc Ther"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1161\/CIRCULATIONAHA.107.689141","article-title":"Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length","volume":"116","author":"Krankenberg","year":"2007","journal-title":"Circulation"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa051303","article-title":"Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery","volume":"354","author":"Schillinger","year":"2006","journal-title":"N Engl J Med"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1161\/CIRCULATIONAHA.107.688341","article-title":"Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting","volume":"115","author":"Schillinger","year":"2007","journal-title":"Circulation"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1161\/CIRCINTERVENTIONS.109.903468","article-title":"Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial","volume":"3","author":"Laird","year":"2010","journal-title":"Circ Cardiovasc Interv"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1583\/11-3627.1","article-title":"Nitinol stent implantation vs. Balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication: three-year follow-up from the RESILIENT randomized trial","volume":"19","author":"Laird","year":"2012","journal-title":"J Endovasc Ther"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1161\/CIRCULATIONAHA.113.001849","article-title":"Stent placement versus balloon angioplasty for the treatment of obstructive lesions of the popliteal artery: a prospective, multicenter, randomized trial","volume":"127","author":"Rastan","year":"2013","journal-title":"Circulation"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/1526602814564386","article-title":"Stent placement vs. Balloon angioplasty for popliteal artery treatment: two-year results of a prospective, multicenter, randomized trial","volume":"22","author":"Rastan","year":"2015","journal-title":"J Endovasc Ther"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s002709900186","article-title":"Buth J, vd Bosch HC. Balloon angioplasty combined with primary stenting versus balloon angioplasty alone in femoropopliteal obstructions: a comparative randomized study","volume":"20","author":"Vroegindeweij","year":"1997","journal-title":"Cardiovasc Intervent Radiol"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S1051-0443(07)61572-3","article-title":"Randomized study to compare PTA alone versus PTA with palmaz stent placement for femoropopliteal lesions","volume":"12","author":"Grimm","year":"2001","journal-title":"J Vascu Interv Radiol"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jcin.2019.12.028","article-title":"A polymer-free paclitaxel-eluting stent versus a bare-metal stent for De Novo femoropopliteal lesions: the BATTLE trial","volume":"13","author":"Gou\u00ebffic","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"e006564","DOI":"10.1161\/CIRCINTERVENTIONS.118.006564","article-title":"Drug-Eluting versus bare-metal stent implantation with or without cilostazol in the treatment of the superficial femoral artery","volume":"11","author":"Miura","year":"2018","journal-title":"Circ Cardiovasc Interv"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jacc.2018.11.039","article-title":"Drug-Eluting stent versus drug-coated balloon revascularization in patients with femoropopliteal arterial disease","volume":"73","author":"Bausback","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jacc.2019.04.057","article-title":"Drug-Eluting balloon versus drug-eluting stent for Complex femoropopliteal arterial lesions: the DRASTICO study","volume":"74","author":"Liistro","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.avsg.2019.06.014","article-title":"Midterm outcome of directional atherectomy combined with drug-coated balloon angioplasty versus drug-coated balloon angioplasty alone for femoropopliteal arteriosclerosis obliterans","volume":"64","author":"Cai","year":"2020","journal-title":"Ann Vasc Surg"},{"key":"2023031404455702300_","first-page":"355","article-title":"The COMPLIANCE 360\u00b0 Trial: a randomized, prospective, multicenter, pilot study comparing acute and long-term results of orbital atherectomy to balloon angioplasty for calcified femoropopliteal disease","volume":"26","author":"Dattilo","year":"2014","journal-title":"J Invasive Cardiol"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.jvir.2011.05.013","article-title":"Percutaneous lower-extremity arterial interventions with primary balloon angioplasty versus Silverhawk atherectomy and adjunctive balloon angioplasty: randomized trial","volume":"22","author":"Shammas","year":"2011","journal-title":"J Vasc Interv Radiol"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0950-821X(05)80235-X","article-title":"Recurrence of stenoses following balloon angioplasty and Simpson atherectomy of the femoro-popliteal segment. A randomised comparative 1-year follow-up study using colour flow duplex","volume":"6","author":"Vroegindeweij","year":"1992","journal-title":"Eur J Vasc Surg"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0741-5214(95)70267-9","article-title":"Directional atherectomy versus balloon angioplasty in segmental femoropopliteal artery disease: two-year follow-up with color-flow duplex scanning","volume":"21","author":"Vroegindeweij","year":"1995","journal-title":"J Vasc Surg"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S1051-0443(96)70857-6","article-title":"Comparison of balloon angioplasty and Simpson atherectomy for lesions in the femoropopliteal artery: angiographic and clinical results of a prospective randomized trial","volume":"7","author":"Tielbeek","year":"1996","journal-title":"J Vasc Interv Radiol"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"e004848","DOI":"10.1161\/CIRCINTERVENTIONS.116.004848","article-title":"Directional atherectomy followed by a paclitaxel-coated balloon to inhibit restenosis and maintain vessel patency: twelve-month results of the DEFINITIVE AR study","volume":"10","author":"Zeller","year":"2017","journal-title":"Circ Cardiovasc Interv"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jvir.2008.02.008","article-title":"Randomized, multicenter study comparing expanded polytetrafluoroethylene-covered endoprosthesis placement with percutaneous transluminal angioplasty in the treatment of superficial femoral artery occlusive disease","volume":"19","author":"Saxon","year":"2008","journal-title":"J Vasc Interv Radiol"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jvs.2013.01.050","article-title":"Three-year results of the VIBRANT trial of VIABAHN endoprosthesis versus bare nitinol stent implantation for complex superficial femoral artery occlusive disease","volume":"58","author":"Geraghty","year":"2013","journal-title":"J Vasc Surg"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.jacc.2013.05.079","article-title":"Heparin-bonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions: the randomized VIASTAR trial (Viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in superficial femoral artery occlusive disease)","volume":"62","author":"Lammer","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00270-014-1024-9","article-title":"Sustained benefit at 2 years for covered stents versus bare-metal stents in long SFA lesions: the VIASTAR trial","volume":"38","author":"Lammer","year":"2015","journal-title":"Cardiovasc Intervent Radiol"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ejvs.2014.02.011","article-title":"Randomized trials for endovascular treatment of infrainguinal arterial disease: systematic review and meta-analysis (part 1: above the knee)","volume":"47","author":"Jens","year":"2014","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ijcard.2021.08.038","article-title":"Comparative effectiveness of endovascular treatment modalities for de novo femoropopliteal lesions in intermittent claudication: a network meta-analysis of randomized controlled trials","volume":"343","author":"Zhou","year":"2021","journal-title":"Int J Cardiol"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1148\/radiology.204.1.9205227","article-title":"Meta-analysis of the results of percutaneous transluminal angioplasty and stent placement for aortoiliac occlusive disease","volume":"204","author":"Bosch","year":"1997","journal-title":"Radiology"},{"key":"2023031404455702300_","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jacc.2011.09.036","article-title":"Classification and clinical impact of restenosis after femoropopliteal stenting","volume":"59","author":"Tosaka","year":"2012","journal-title":"J Am Coll Cardiol"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/44\/11\/935\/49520009\/ehac722.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/44\/11\/935\/49520009\/ehac722.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T19:50:46Z","timestamp":1678823446000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/44\/11\/935\/7017608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,31]]},"references-count":93,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,1,31]]},"published-print":{"date-parts":[[2023,3,14]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehac722","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,3,14]]},"published":{"date-parts":[[2023,1,31]]}}}